Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes

摘要

Immune checkpoint inhibitors (CPI) have proven remarkably effective in treating many types of malignancies but have been associated with significant risk for immune-related adverse events (irAEs) ( ). Among these, new onset of insulin-dependent diabetes mellitus (DM) occurs in 0.2–1.0% of patients ( , ) and is being seen more frequently as CPI become more widely used. However, the incidence, clinical course, and pathogenesis of CPI-associated DM (CPI-DM) are not well understood.